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•Recombinantglucocerebrosidase(GBA):enzymeusedforreplacement
therapy of Type I Gaucher disease, a lysosomal storage disorder
•Exposure of terminal mannose residues is important to increase
GBA delivery to pathological macrophages: enzymatic deglycosylation
of the commercially available CHO-derived Cerezyme® (Genzyme)
•Previous work at our laboratory (Gutierrez, 2010) developed GBA-
producing clones derived from different CHO parental cell lines,
including glycosylation mutants
•Focus of the present study: upstream process development based
on evaluation of temperature reduction, supplementation of the
culture medium with a productivity enhancer and perfusion
- DOE to investigate mild hypothermic conditions and valeric acid
supplementation for two cell lines (CHO-GBA-36K, CHO-GBA-65P)
- Perfusion operation under the selected conditions, with the aim to




•CHO-GBA-36K and CHO-GBA-65P were cultivated in TC-LECC (Xell
AG, Germany), a customized CD, ADCF medium
•A 22 DOE was performed in spinner flasks for each cell line (Table 1)
Table 1. DOE for evaluation of the effects of 
valeric acid supplementation and mild hypothermia.
•Perfusion process
•stirred tank bioreactor (RALF, BioEngineering AG)
•pH 7.1, 150 rpm, 40% air saturation, 37oC with shift to 31oC (d7)
•CS-10 inclined settler (Biotechnology Solutions)
•perfusion start when target viable cell concentration reached
•dilution rate in increasing steps: 0.5, 0.75, 1 and 2 vvd
•Analytical
•Viable cell density (VCD) and cell viability were determined by
trypan blue exclusion method using a Neubauer chamber in an
optical microscope (Eclipse TS100, Nikon) or using an automatic
counter equipment (Vi-Cell XR, Beckman Coulter)
•GBA enzyme activity in the samples was determined by measuring
the release of the fluorescent compound 4-methylumbelliferone
(4-MU) upon hydrolysis of the synthetic substrate 4-methyl
umbelliferyl-β-D-glucopyranoside (4-MUD, Sigma, M3633). The
fluorescent product was quantified with a fluorescence microplate
reader (Victor III, Perkin Elmer) using excitation and emission filters
of 355 nm and 460 nm, respectively
•Glucose and lactate were measured using a YSI2700 analyser
(Yellow Springs Instruments)
Runs and replicates Valeric Acid Temperature
[1] (n=2) -1 (0 mM) -1 (31 °C)
[2]   (n=2) -1 (0 mM) +1 (37 °C)
[3] (n=2) +1 (2 mM) -1 (31 °C)
[4] (n=2) +1 (2 mM) +1 (37 °C)
[5] (n=3) 0 (1 mM) 0 (34 °C)
Fig 1. Specific productivity (qP) for the different DOE conditions using CHO-GBA-
65P (A) and CHO-GBA-36K (B) cells. Under condition [1] (31oC, no valeric acid),
CHO-GBA-65P achieved a maximum qP of 58.4 nU/cell/d, which was 4.2 fold
higher than qP at the control condition [2] and 2.7 fold higher than the
maximum qP obtained for the CHO-GBA-36K clone, which was achieved at 31
oC
with 2 mM valeric acid supplementation (condition [3]).
Fig 2. Perfusion process using CHO-GBA-65P clone. Perfusion was started on
day 3, and a temperature downshift to 31°C was applied on day 7. The
application of a perfusion rate of 2 vvd enabled cell densities up to 50E6
cells/mL to be achieved.
o For both cell clones, a subphysiological temperature of 31oC led to an increase in the specific productivity (qP), but the effect of valeric acid supplementation was
clone dependent.
o The best overall performance regarding both cell growth and productivity was obtained for the CHO-GBA-65P cell clone at 31°C without valeric acid.
o The maximum product titer achieved in perfusion was 9.5-fold higher compared to batch at 31°C and 22-fold higher than the control batch (at 37oC).
o Perfusion typically results in higher volumetric productivities but lower titers. However, for this enzyme, our results show that a biphasic perfusion strategy
including a temperature downshift can significantly enhance also GBA titer in the harvest, which is an advantage for subsequent downstream processing.
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